



Tasnim
Pharmaceutical Co.

ERX : 69867

Tasnim Pharmaceutical Co.

Alzixa[®] E.R. **7**

Memantine

Each Capsule Contains:
Memantine HCl 7 mg

30 Extended Release Capsules

ERX : 69867

Tasnim Pharmaceutical Co.

Alzixa[®] E.R. **14**

Memantine

Each Capsule Contains:
Memantine HCl 14 mg

30 Extended Release Capsules

ERX : 69869

Tasnim Pharmaceutical Co.

Alzixa[®] E.R. **21**

Memantine

Each Capsule Contains:
Memantine HCl 21 mg

30 Extended Release Capsules

ERX :

Tasnim Pharmaceutical Co.

Alzixa[®] E.R. **28**

Memantine

Each Capsule Contains:
Memantine HCl 28 mg

30 Extended Release Capsules

Start



Click Here To Start


CONTACT US

GUIDE

If you can't use the buttons, you can scroll down to the bottom of document to view the guide.

Copyright © 2022 Tasnim - All Rights Reserved.

Designed & Executed by ClickBan Co.



Menu


SELECT AN OPTION TO CONTINUE;




Home



About Alzixa E.R.



Details



Category & Indication



Mechanism Of Action



Adverse Effects



Articles



Contact Tasnim



Guide

ALZIXA[®] E.R.
Smart Catalog



Home

Alzixa® E.R.

ERX(7mg) : ERX(14mg) : 69867
ERX(21mg) : 69869 ERX(28mg) :

Drug Brand

Alzixa® E.R.

Generic Name

Memantine
hydrochloride

Drug form



Extended Release
Capsule, 7 & 14 &
21 & 28 mg

Package

3 blisters of 10 Extended
Release Capsule in a box

[Start Exploring](#)

Problem with buttons? [View Guide](#)



What is Alzixa[®] E.R.?

- Memantine is an antagonist of the NMDA (N-Methyl-D-Aspartate)-receptor subtype of glutamate receptor. It is used to slow the neurotoxicity thought to be involved in Alzheimer disease and other neurodegenerative.

1

2

>



What is Alzixa[®] E.R.?

- Memantine blocks the NMDA-receptor subtype of glutamate receptors preventing over-activation of glutamine receptors while allowing the normal activity. Its blocking effects antagonize an overactive glutaminergic system in the central nervous system (CNS) which is thought to be involved in the neurotoxicity seen in Alzheimer disease.

<

1

2



Details

Dosage & Administration

Interactions

Breast feeding & pregnancy

View Pictures

More information



Dosage & Administration

Oral:

- Extended release: Initial: 7 mg once daily; increase daily dose by 7 mg every week as tolerated to a target maximum dose of 28 mg once daily.
- Conversion from immediate release to extended release: Begin the ER product the day after the last dose of the IR product

1

2

>



Dosage & Administration

If current IR dose is 10 mg/day: Convert to ER capsule 14 mg once daily.

If current IR dose is 20 mg/day: Convert to ER capsule 28 mg once daily.

Missed doses: If several days of dosing are missed with either formulation, dosing may need to be resumed at lower doses and retitrated.

<

1

2



Interactions

- Alkalinizing Agents: May increase the serum concentration of Memantine. Risk C: Monitor therapy
- Benperidol: Memantine may diminish the therapeutic effect of Benperidol. Risk C: Monitor therapy.
- Carbonic Anhydrase Inhibitors: May increase the serum concentration of Memantine. Risk C: Monitor therapy
- NMDA Receptor Antagonists: May enhance the adverse/toxic effect of Memantine. Risk C: Monitor therapy

1

2

>



Interactions

- Trimethoprim: May enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. Memantine may increase the serum concentration of Trimethoprim. Risk C: Monitor therapy

<



1

2



Breast Feeding & Pregnancy

Pregnancy Category B



Alzixa® E.R.

Pictures



Alzixa® E.R. 7mg

1

2

3

4

>






Alzixa® E.R.

Pictures




Alzixa® E.R. 14mg





Alzixa® E.R.

Pictures



Alzixa® E.R. 21mg




Alzixa® E.R.

Pictures



Alzixa® E.R. 28mg





More Information


Mean (\pm SD) Memanatine Plasma Concentrations vs Time over the -24hour Dosing Interval at steady Following once-daily administration.

Transition to Alzixa[®]E.R.

Dosing conversions from the immediate release tablets to the Extended release capsules



Mean (\pm SD) Memantine Plasma Concentrations vs Time over the -24hour Dosing Interval at steady Following once-daily administration.



Transition to Alzixa® E.R.

Alzixa® 5
Twice a day today



Alzixa® E.R. 7
Once a day tomorrow

Alzixa® 5
Twice a day today



Alzixa® E.R. 14
Once a day tomorrow

Alzixa® 10+5
Twice a day today





Alzixa® E.R. 21
Once a day tomorrow

Alzixa® 10+10
Twice a day today



Alzixa® E.R. 28
Once a day tomorrow



Dosing conversions from Immediate release tablets to the Extended release capsules

Alzixa [®] Immediate release(IR)	Alzixa [®] E.R. Extended release(ER)
5mg/day	7mg/day
10mg/day	14mg/day
15mg/day	21mg/day
20mg/day	28mg/day



Category & Indication

- N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
- Treatment of moderate to severe Alzheimer dementia (monotherapy or in combination with a cholinesterase inhibitor)
- Use: Off-Label

1

2

>



Category & Indication

- Dementia (ie, Parkinson disease dementia, dementia with Lewy bodies, comorbid vascular dementia) (monotherapy or in combination with a cholinesterase inhibitor)
- Neurocognitive toxicity of whole brain irradiation, prevention

<

1

2



Mechanism Of Action

Alzixa[®]E.R. (Memantine) is an antagonist of the NMDA (N-Methyl-D-Aspartate)-receptor subtype of glutamate receptor. It is used to slow the neurotoxicity thought to be involved in Alzheimer disease and other neurodegenerative diseases.

Glutamate, the primary excitatory amino acid in the CNS, may contribute to the pathogenesis of Alzheimer's disease (AD) by overstimulating various glutamate receptors leading to excitotoxicity and neuronal cell death.

1

2

3

>



Mechanism Of Action

Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) type of glutamate receptors, located ubiquitously throughout the brain. Under normal physiologic conditions, the (unstimulated) NMDA receptor ion channel is blocked by magnesium ions, which are displaced after agonist-induced depolarization.



Mechanism Of Action

Pathologic or excessive receptor activation, as postulated to occur during AD, prevents magnesium from reentering and blocking the channel pore resulting in a chronically open state and excessive calcium influx.

Memantine binds to the intra-pore magnesium site, but with longer well time, and thus functions as an effective receptor blocker only under conditions of excessive stimulation; memantine does not affect normal neurotransmission.

<

1

2

3



Adverse Effects

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions similar in immediate and extended release formulations except as noted.

1% to 10%:



Cardiovascular: Hypertension (4%), hypotension (ER: 2%)

Endocrine & metabolic: Weight gain (ER: 3%)

Gastrointestinal: Abdominal pain (ER: 2%), constipation (3% to 5%), diarrhea (ER: 5%), vomiting (2% to 3%)

Genitourinary: Urinary incontinence (ER: 2%)

Nervous system: Aggressive behavior (ER: 2%)



Articles

Leaflet



Memantine ER Response in Moderate to Severe Alzheimer's Disease



The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg)





Critical appraisal and role of memantine extended-release in Alzheimer's disease



Extended-Release Memantine (28 mg, Once Daily) in Behavioral in Moderate to Severe Alzheimer's Disease



Clinical Benefits of Extended-Release Memantine (28 mg, once daily)




Alzixa[®] E.R.

Contact Us



+98 21 88 17 4810



tasnimpharmaceutical



tasnimpharma.com



info@tasnimpharma.com



NO. 3 , 14th East Alley ,
Beyhaghi Blvd. , Argentina Sq. ,
Tehran , Iran

TAP FOR DIRECTIONS 



GUIDE

If you have conflicts while interacting with this catalog, this guide will help you.

If you are using iPhone, Mac OS or Windows, you probably won't have any problem with the buttons.

But if you are using an Android device, you must have [Google Drive](#) installed and updated.

In the next steps you'll see the frequently used buttons that are important.

SKIP


NEXT STEP

Problem with buttons? [View Guide](#)





Here you can see the **navigation bar** which is fixed on left in the document.



Alzixa[®] E.R.

Drug Brand | Alzixa[®]E.R.

You can tap on each of these icons to navigate to its page.

Generic Name | Memantine hydrochloride

Drug form | Extended Release Capsule, 7 & 14 & 21 & 28 mg

Package | 3 blisters of 10 Extended Release Capsule in a box

SKIP

NEXT STEP


Start Exploring

Problem with buttons? [View Guide](#)





Tap this icon to go back to [previous page](#) or menu.



Alzixa® E.R.

Drug Brand

Alzixa® E.R.

GO BACK TO THE CATALOG

Drug form

Extended Release Capsule, 7 & 14 & 21 & 28 mg

Tap this icon to go to the [next page](#).

Package

21 lists of 10 Extended Release Capsule in a box

Start Exploring

Problem with buttons? [View Guide](#)

